References.
  1. Pearson ADJ, Rossig C, Lesa G, et al . ACCELERATE and European medicines agency paediatric strategy forum for medicinal product development of checkpoint inhibitors for using combination therapy in paediatric patients. Eur J Cancer 2020; 127 : 52-66.
  2. Siegel RL, Miller KD, Jemel A. Cancer statics. CA Cancer J Clin 2016; 66 : 7-30.
  3. PDQ® Pediatric Treatment Editorial Board. PDQ cancer Information Summaries [Internet] . Late effect pf treatment. Bethesada (MD), National Cancer Institute 2002-2020.2020,Feb 4.
  4. Leung W, Naele G, Behm F, et al. Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiology 2010; 34: 303-308
  5. Takahashi R, Ishibashi Y, Hiraoka K, et al . Phase Ⅱ study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Sci 2013; 104:1285-1294.
  6. Iwasa S, Yamada Y, Heike Y, et al. PhaseⅠstudy of a new cancer vaccine of ten mixed peptides for advancer cancer patients. Cancer Sci 2016; 107: 590-600.
  7. Takahashi R, Toh U, Iwakuma N, et al . Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Resarch 2014; 16: R70.
  8. Noguchi M, Moriya F, Koga N et al . A randomized phase Ⅱ clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother 2016; 65 :151-60.
  9. Suekane S, Ueda K, Nishihara K, et al . Personalized peptide vaccination as a second line treatment for metastatic upper tract urothelial carcinoma. Cancer Sci 2017; 108 :2430-2437.
  10. Sakamoto S, Yutani S, Schichijo S, et al . Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site. Cancer Immuno Immunother 2016; 65: 1223-1231.
  11. Sakamoto S, Matsueda S, Takamori S, et al . Immunological evaluation of personalized peptide vaccination for cancer patients with the HLA-A26 allele. Cancer Sci 2015; 106: 1257-1263.
  12. Komatsu N, Shichijo S, Nakagawa M, et al . New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Laborat Invest 2004; 64: 535-546.
  13. Chen C, Garcia HK, Sheer M. Current and future treatment strategies for Rhabdomyosarcoma. Front Oncol 2019; 9:1958.
  14. Camero S, Ceccarelli S, De Feris M, et al . PARP inhibitors affects survival, radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines. J Cancer Res Clin Oncol 2019; 145:137-152.
  15. Stewart E, Mcvoy J, Wang H, et al . Identification of therapeutic targets-rhabdomyosarcoma integrated genomic, epigenomic, and proteomic analysis. Cancer cell 2018; 34 : 411-426.
  16. Hawkins DS, Chi YY, Anderson R, et al. Additional vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma : a report from the Children’s Oncology Group. J Clin Oncol 2018; 36 : 2770-2777.
  17. Kim JR, Yoon HM, Koh KM, et al. Rhabdomyosarcoma in children and adolescents : patterns and risk factors of distant metastasis. Am J Roentgenol 2017; 209 :409-416.
  18. Amer KM, Thomson JE, Conquesta G, et al . Epidemiology, incidence and survival of rhabdomyosarcoma subtypes : SEER and ICES data base analysis. J Orthop Res 2019; 37: 2226-2230.
  19. Hashii Y, Sato E, Ohta H, et al. WT1 Peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer 2010; 55:352-355.